FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to the use of an antibody that binds to claudin to produce a medicament for the treatment or prevention of cancer metastases in lymph nodes.
EFFECT: obtaining a medicament for the treatment or prevention of lymph node metastases.
50 cl, 39 dwg, 8 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30 | 2006 |
|
RU2492186C2 |
COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
RECOVERED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND METHOD OF INHIBITION OF PSMA-EXPRESSING CELL GROWTH | 2006 |
|
RU2421466C2 |
Authors
Dates
2019-03-18—Published
2008-05-27—Filed